U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07321886) titled 'A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes' on Jan. 05.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Intervention:
DRUG: Eloralintide
Administe...